RecruitingNot ApplicableNCT07402109
CBCT Guided Markerless SBRT for Renal Cell Cancer
Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors
Sponsor
Erasmus Medical Center
Enrollment
40 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence
- No metastatic lesions
- Patients must be 18 years or older
- Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.
- Written informed consent
Exclusion Criteria1
- Previous high-dose radiotherapy in the region of the kidney
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONAdditional radiation due to imaging
Additional imaging will be done using CT, therefore the patient will receive additional radiation dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07402109
Related Trials
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT074198413 locations
Validation of RCC Predicting Model With Emulated-target Trial
NCT071172271 location
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720409 locations
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
NCT071975805 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483122 locations